Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/165499
Full metadata record
DC FieldValueLanguage
dc.contributor.authorArbeláez-Camargo, Diana-
dc.contributor.authorRoig Carreras, Manel-
dc.contributor.authorGarcía Montoya, Encarna-
dc.contributor.authorPérez Lozano, Pilar-
dc.contributor.authorMiñarro Carmona, Montserrat-
dc.contributor.authorTicó Grau, Josep R.-
dc.contributor.authorSuñé i Negre, Josep M. (Josep Maria)-
dc.date.accessioned2020-06-15T07:02:54Z-
dc.date.available2020-06-15T07:02:54Z-
dc.date.issued2018-05-30-
dc.identifier.issn0378-5173-
dc.identifier.urihttp://hdl.handle.net/2445/165499-
dc.description.abstractDuring the development of parenteral dosage forms, different physicochemical studies are required to ensure stable, effective and safe formulations. The osmolality of this kind of dosage forms should bear a close similarity to the body fluids to prevent local irritation, pain or even more significant side effects like endothelial damage. The osmotic studies performed in Polyethylene glycol 400 (PEG 400), Polyethylene glycol 4000 (PEG 4000), Poloxamer 407 (P407), Sodium Hyaluronate (SH), Chondroitin Sulphate Sodium (CS), Cremophor RH 40 (CRE40) and Polyvinyl alcohol (PVA) aqueous solutions, showed that the theoretical determination of the osmolality based on their molecular weight as the only determinant factor did not agree with the values obtained by the measurement of colligative properties such as the freezing point depression. The data obtained from this study and its analysis, provided predictive equations that can be used as tools in the primary development to estimate formulation's osmolality at different concentrations; and its evolution over a period at the hypothetical worst-case scenario of storage temperature.-
dc.format.extent11 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier B.V.-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.ijpharm.2018.03.052-
dc.relation.ispartofInternational Journal of Pharmaceutics, 2018, vol. 543, num. 1-2, p. 190-200-
dc.relation.urihttps://doi.org/10.1016/j.ijpharm.2018.03.052-
dc.rightscc-by-nc-nd (c) Elsevier B.V., 2018-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es-
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)-
dc.subject.classificationFormes farmacèutiques-
dc.subject.classificationModels moleculars-
dc.subject.classificationPolímers-
dc.subject.classificationTemperatura-
dc.subject.otherPharmaceutical dosage forms-
dc.subject.otherMolecular models-
dc.subject.otherPolymers-
dc.subject.otherTemperature-
dc.titleOsmolality predictive models of different polymers as tools in parenteral and ophthalmic formulation development.-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.identifier.idgrec681311-
dc.date.updated2020-06-15T07:02:54Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
681311.pdf1 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons